The overall prevalence rate was 3.81 per 100000, this equates to an estimated 2400 prevalent cases in the UK. The overall and relative 5-year survival rates were 72% and 82.7%, respectively.#This study showed that classical haemolytic PNH is a rare disease and represents only a small ...
March 20th 2025 Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS Rose McNulty The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies. ...
Transfusion avoidance rate, % (95% CI) 87.6 (81.1 to 94.2) 82.7 (75.2 to 90.2) Difference in rate 5.5 (−4.3 to 15.7) −20% Noninferior Stabilized hemoglobin rate, % (95% CI) 76.3 (67.8 to 84.8) 75.5 (67.0 to 84.0) Difference in rate 1.4 (−10.4 to 13.3) −20% Noninfer...
aHUS (estimated glomerular filtration rate [eGFR] of 5 mL/min/1.73 m2 to105 mL/min/1.73 m2 using the Modification of Diet in Renal Disease [MDRD] formula), or gMG patients (eGFR of 44 mL/min/1.73 m2 to 168
The overall prevalence rate was 3.81 per 100 000, this equates to an estimated 2400 prevalent cases in the UK. The overall and relative 5‐year survival rates were 72% and 82.7%, respectively. Conclusions This study showed that classical haemolytic PNH is a rare disease and represents only ...
Overall survival (OS) was mainly influenced by age and was similar to OS measured in an age-matched healthy Austrian control cohort. Together, compared with previous times, the clinical course and OS in PNH are favorable, which may be due to better diagnosis, early recognition, and eculizumab...
Kaplan-Meier 10-year survival estimate was 76.3% (± 2.6). Sixty seven (14.6%) patients developed pancytopenia during follow-up [10-year cumulative incidence (CIn) rate of 18.3% (14% – 22%)]. Deep-vein thrombosis occurred in 108 patients (23.5%) [10-year CIn 28% (23% – 33.1%)]...
GLOMERULAR filtration rateObjectives: Data from the International PNH Registry (NCT01374360) were used to estimate the overall survival and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) ...